{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:41:43Z","timestamp":1788406903052,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","award":["SZSM201812002"],"award-info":[{"award-number":["SZSM201812002"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013093","name":"Science and Technology Planning Project of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JCY20170303155201082"],"award-info":[{"award-number":["JCY20170303155201082"]}],"id":[{"id":"10.13039\/501100013093","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen Key Medical Discipline Construction Fund","award":["SZGSP012"],"award-info":[{"award-number":["SZGSP012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Aicardi-Gouti\u00e8res (AGS) is a rare immune dysregulated disease due to mutations in\n                      <jats:italic>TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1,<\/jats:italic>\n                      or\n                      <jats:italic>IFIH1.<\/jats:italic>\n                      Clinical features include basal ganglia calcifications, white matter abnormalities, and cerebral atrophy. Severe systemic inflammation and chronic kidney disease (CKD) are extremely rare in AGS. Herein, we report a patient presenting with systemic inflammation and CKD to broaden the clinical phenotype spectrum of the\n                      <jats:italic>RNASEH2B<\/jats:italic>\n                      defect.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All testing and molecular genetic analysis were performed after obtaining the informed consent of the parents. Demographic, clinical, and laboratory findings were abstracted from outpatient and inpatient encounters. Cerebral magnetic resonance imaging (MRI), computed tomography (CT) scans, and renal biopsy histopathology reports were reviewed and summarized. Whole exome sequencing (WES) was performed on peripheral blood cells. After exposure to cGAMP in vitro for 24\u2009h, mRNA expression of 12 IFN-stimulated cytokine genes in PBMCs was assessed. Serum cytokine levels were detected by Milliplex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A 11-year-old girl presented with recurrent aseptic fever, arthritis, chilblains, failure to thrive, mild hearing loss, and neurological manifestations. Laboratory and immunologic findings demonstrated lymphopenia, low complement levels, positive autoantibodies, elevated levels of acute-phase reactants and inflammatory cytokines. Cerebral imaging showed cerebral atrophy, white matter abnormalities, and intracranial calcification. Renal biopsy showed glomerular sclerosis in 3 of 14 glomeruli, infiltration of lymphocytes and other mononuclear cells. WES revealed a homozygous and heterozygous mutations in\n                      <jats:italic>RNASEH2B<\/jats:italic>\n                      . Over-expression of IFN-stimulated cytokine genes was observed, including IFI44, IFI27, IFIT1, IFIT2, IFIT3, ISG15, OAS1, and SIGLEC1.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      To date, only two cases with AGS have been reported to have renal disease. Here, we describe a patient with both homozygous and heterozygous variants in\n                      <jats:italic>RNASEH2B,<\/jats:italic>\n                      presenting with neurological manifestations, persistently systemic autoinflammation, and CKD. CKD has never been reported in patients with AGS due to the\n                      <jats:italic>RNASEH2B<\/jats:italic>\n                      defect\n                      <jats:italic>.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Not applicable; this was a retrospective study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-021-00497-2","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T03:03:37Z","timestamp":1611284617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Systemic inflammation and chronic kidney disease in a patient due to the RNASEH2B defect"],"prefix":"10.1186","volume":"19","author":[{"given":"Tingyan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"issue":"8","key":"497_CR1","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.4049\/jimmunol.1401334","volume":"194","author":"E Cuadrado","year":"2015","unstructured":"Cuadrado E, Michailidou I, van Bodegraven EJ, Jansen MH, Sluijs JA, Geerts D, et al. Phenotypic variation in Aicardi-Goutieres syndrome explained by cell-specific IFN-stimulated gene response and cytokine release. J Immunol. 2015;194(8):3623\u201333.","journal-title":"J Immunol"},{"issue":"2","key":"497_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ajmg.a.36887","volume":"167A","author":"YJ Crow","year":"2015","unstructured":"Crow YJ, Chase DS, Lowenstein SJ, Szynkiewicz M, Forte GM, Gornall HL, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A. 2015;167A(2):296\u2013312.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"497_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1172\/JCI78001","volume":"125","author":"C G\u00fcnther","year":"2015","unstructured":"G\u00fcnther C, Kind B, Reijns MAM, Berndt N, Martinez-Bueno M, Wolf C, et al. Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J Clin Invest. 2015;125(1):413\u201324.","journal-title":"J Clin Invest"},{"issue":"1","key":"497_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-018-0224-2","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze CH, Holzinger D, Lainka E, Haas JP, Speth F, Kallinich T, et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J. 2018;16(1):7.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"9","key":"497_CR5","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/1756-185X.13649","volume":"22","author":"K Barut","year":"2019","unstructured":"Barut K, Adrovic A, Sahin S, Tarcin G, Tahaoglu G, Koker O, et al. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience. Int J Rheum Dis. 2019;22(9):1661\u20139.","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"497_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/BOR.0000000000000526","volume":"30","author":"S Yasin","year":"2018","unstructured":"Yasin S, Schulert GS. Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment. Curr Opin Rheumatol. 2018;30(5):514\u201320.","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"497_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11926-011-0165-y","volume":"13","author":"R Goldbach-Mansky","year":"2011","unstructured":"Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID\/CINCA. Curr Rheumatol Rep. 2011;13(2):123\u201331.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"497_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13023-016-0542-8","volume":"11","author":"M Finetti","year":"2016","unstructured":"Finetti M, Omenetti A, Federici S, Caorsi R, Gattorno M. Chronic Infantile Neurological Cutaneous and Articular (CINCA) syndrome: a review. Orphanet J Rare Dis. 2016;11(1):167.","journal-title":"Orphanet J Rare Dis"},{"key":"497_CR9","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3389\/fimmu.2020.00985","volume":"11","author":"S Zheng","year":"2020","unstructured":"Zheng S, Lee PY, Wang J, Wang S, Huang Q, Huang Y, et al. Interstitial lung disease and psoriasis in a Child with Aicardi-Gouti\u00e8res syndrome. Front Immunol. 2020;11:985.","journal-title":"Front Immunol"},{"issue":"2","key":"497_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5692\/clinicalneurol.cn-001096","volume":"58","author":"R Komaki","year":"2018","unstructured":"Komaki R, Ueda T, Tsuji Y, Miyawaki T, Kusuhara S, Hara S, et al. Retinal vasculopathy with cerebral leukoencephalopathy carrying TREX1 mutation diagnosed by the intracranial calcification: a case report. Rinsho Shinkeigaku. 2018;58(2):111\u20137.","journal-title":"Rinsho Shinkeigaku"},{"issue":"3","key":"497_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1089\/jir.1981.1.347","volume":"1","author":"V Bocci","year":"1981","unstructured":"Bocci V, Pacini A, Muscettola M, Paulesu L, Pessina GP, Santiano M, et al. Renal filtration, absorption and catabolism of human alpha interferon. J Interferon Res. 1981;1(3):347\u201352.","journal-title":"J Interferon Res"},{"issue":"6","key":"497_CR12","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s10067-017-3600-2","volume":"36","author":"M Henrickson","year":"2017","unstructured":"Henrickson M, Wang H. Tocilizumab reverses cerebral vasculopathy in a patient with homozygous SAMHD1 mutation. Clin Rheumatol. 2017;36(6):1445\u201351.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"497_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/1744666X.2019.1707663","volume":"16","author":"D Tonduti","year":"2020","unstructured":"Tonduti D, Fazzi E, Badolato R, Orcesi S. Novel and emerging treatments for Aicardi-Goutieres syndrome. Expert Rev Clin Immunol. 2020;16(2):189\u201398.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"497_CR14","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.jaci.2018.12.1012","volume":"143","author":"AA de Jesus","year":"2019","unstructured":"de Jesus AA, Brehm A, VanTries R, Pillet P, Parentelli AS, Montealegre SG, et al. Novel proteasome assembly chaperone mutations in PSMG2\/PAC2 cause the autoinflammatory interferonopathy CANDLE\/PRAAS4. J Allergy Clin Immunol. 2019;143(5):1939\u201343.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"497_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jaci.2016.10.031","volume":"140","author":"I Melki","year":"2017","unstructured":"Melki I, Rose Y, Uggenti C, Van Eyck L, Fremond ML, Kitabayashi N, et al. Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling. J Allergy Clin Immunol. 2017;140(2):543\u201352.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"497_CR16","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","volume":"128","author":"G Sanchez","year":"2018","unstructured":"Sanchez G, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041\u201352.","journal-title":"J Clin Invest"},{"issue":"6","key":"497_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1212\/WNL.0000000000004921","volume":"90","author":"K Kothur","year":"2018","unstructured":"Kothur K, Bandodkar S, Chu S, Wienholt L, Johnson A, Barclay P, et al. An open-label trial of JAK 1\/2 blockade in progressive IFIH1-associated neuroinflammation. Neurology. 2018;90(6):289\u201391.","journal-title":"Neurology"},{"issue":"5","key":"497_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/art.40805","volume":"71","author":"K Meesilpavikkai","year":"2019","unstructured":"Meesilpavikkai K, Dik WA, Schrijver B, van Helden-Meeuwsen CG, Versnel MA, van Hagen PM, et al. Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi-Goutieres Syndrome, a Type I Interferonopathy. Arthritis Rheumatol. 2019;71(5):829\u201331.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"497_CR19","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1161\/ATVBAHA.118.311504","volume":"38","author":"I Parra-Izquierdo","year":"2018","unstructured":"Parra-Izquierdo I, Castanos-Mollor I, Lopez J, Gomez C, San RJ, Sanchez CM, et al. Calcification induced by type I interferon in human Aortic valve interstitial cells is larger in males and blunted by a janus kinase inhibitor. Arterioscler Thromb Vasc Biol. 2018;38(9):2148\u201359.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"497_CR20","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1136\/annrheumdis-2016-210565","volume":"75","author":"V Tungler","year":"2016","unstructured":"Tungler V, Konig N, Gunther C, Engel K, Fiehn C, Smitka M, et al. Response to: \u2018JAK inhibition in STING-associated interferonopathy\u2019 by Crow. Ann Rheum Dis. 2016;75(12):e76.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"497_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dmcn.14268","volume":"62","author":"YJ Crow","year":"2020","unstructured":"Crow YJ, Shetty J, Livingston JH. Treatments in Aicardi-Goutieres syndrome. Dev Med Child Neurol. 2020;62(1):42\u20137.","journal-title":"Dev Med Child Neurol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00497-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-021-00497-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00497-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T03:16:38Z","timestamp":1611285398000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00497-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["497"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00497-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-33775\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-33775\/v2","asserted-by":"object"}]},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"5 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participated family members were enrolled upon approval of the ethics committee of Shenzhen Children\u2019s hospital and written consent of all the families.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent for publication of this anonymous information was obtained from the patient\u2019s parents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}